COEP Coeptis Therapeutics: Utang jangka cendhak perusahaan

The development of innovative therapies for hematological tumors is in its early stages, which keeps the operating leverage in negative territory for Coeptis Therapeutics (COEP). The short-term debt portfolio allows for the tracking of liability dynamics, while 0.00 reflects the latest value of the metric. High barriers to entry are driven by strict FDA oversight and patents. Business flexibility is ensured by the full outsourcing of production and clinical trials to external contractors.

Short-term debt reflects the aggregate of obligations with a maturity of up to one year, measuring the issuer's ability to service current loans without compromising solvency. By analyzing changes in the amount of short-term borrowings, an investor assesses the risk of a liquidity shortfall, which is critically important for Coeptis Therapeutics (COEP) when financing costly developments in modified cell therapy and diversifying oncology platforms.